The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study

Hannah K. Knudsen, Paul M. Roman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

To consider how the Affordable Care Act may impact the diffusion of acamprosate, an evidence-based treatment for alcohol use disorder (AUD), the present study estimated the associations between acamprosate availability, Medicaid revenues, and private insurance revenues. Data were collected from organizational leaders of national samples of 307 specialty treatment centers in 2009-2012 and 372 treatment centers in 2011-2013. Notably, there was not a significant change in the percentage of organizations offering acamprosate over the study period. However, greater reliance on Medicaid and private insurance as sources of revenue was positively associated with the availability of acamprosate. In addition, acamprosate availability was positively associated with access to physicians and the presence of on-site primary medical care, while centers that placed greater emphasis on confrontational group therapy were significantly less likely to offer acamprosate for AUD treatment. To the extent that the ACA is expanding the number of insured individuals enrolled in Medicaid and commercial insurance sold through health insurance exchanges, this study suggests that the ACA may hold promise for expanding the availability of this EBP for AUD treatment. Future research is needed to measure whether this potential impact actually occurs within the specialty treatment system over time.

Original languageEnglish
Pages (from-to)62-67
Number of pages6
JournalJournal of Substance Abuse Treatment
Volume62
DOIs
StatePublished - Mar 1 2016

Bibliographical note

Funding Information:
This research was supported by funding from the National Institute on Alcohol Abuse and Alcoholism (NIAAA Grant R01AA015974), an institute within the National Institutes of Health (NIH). Beyond this research funding, NIAAA and NIH had no further role in the research design, data analysis, or preparation of this manuscript. The content of this manuscript is solely the responsibility of the authors and does not represent the official views of the NIH or NIAAA. The authors have no conflicts of interest.

Funding Information:
This research was supported by funding from the National Institute on Alcohol Abuse and Alcoholism (NIAAA Grant R01AA015974), an institute within the National Institutes of Health (NIH). Beyond this research funding, NIAAA and NIH had no further role in the research design, data analysis, or preparation of this manuscript. The content of this manuscript is solely the responsibility of the authors and does not represent the official views of the NIH or NIAAA. The authors have no conflicts of interest.

Publisher Copyright:
© 2015 Elsevier Inc.

Keywords

  • Acamprosate
  • Affordable care act
  • Alcohol use disorder
  • Health reform
  • Insurance
  • Medicaid

ASJC Scopus subject areas

  • Psychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study'. Together they form a unique fingerprint.

Cite this